-
After Cuba beckons, Miami entrepreneurs are mostly reluctant to invest in the island
-
Peru's crowded presidential race zeroes in on organized crime
-
Taiwan's Lin to compete in first international event since Paris gender row
-
BTS takes over central Seoul for comeback concert
-
Jury signals tech titans on hook for social media addiction
-
Brumbies mark Slipper record in thriller against Chiefs
-
US jury finds Elon Musk misled Twitter shareholders
-
Gauff rallies to avance at Miami Open
-
WNBA, players union confirm agreement on 'groundbreaking' labor deal
-
Carrick 'baffled' by inconsistent penalty calls as Man Utd held
-
Trump says considering 'winding down' Iran war but rules out ceasefire
-
Trump mulls 'winding down' Iran war
-
Man Utd held by Bournemouth after Maguire sees red
-
Lens go top of Ligue 1 with handsome Angers win
-
Leipzig pummel Hoffenheim to climb to third
-
Quinn ousts 11th seed Ruud at rain-hit Miami Open
-
Rap group Kneecap says crisis-hit Cuba being 'strangled'
-
Anthony, Jackson nail US double at world indoors
-
Zarco seizes his moment as rain disrupts Brazil MotoGP practice
-
Chuck Norris, roundhouse-kicking action star, dead at 86
-
US newcomer Anthony crowned world indoor sprint king
-
Trump rules out Iran truce as more Marines head to Middle East
-
Costa Rican ex-security minister extradited to US for drug trafficking
-
Trump slams NATO 'cowards' as more Marines head to Middle East
-
Gulf's decades-long strategy of sporting investment rocked by Mideast war
-
Souped-up VPNs play 'cat and mouse' game with Iran censors
-
Attacked Russian tanker drifting toward Libya: Italian authorities
-
Coroner 'not satisfied' boxer Hatton intended to take own life
-
Stocks drop, as oil rises as Mideast war persists
-
Vanishing glacier on Germany's highest peak prompts ski lift demolition
-
Chuck Norris, roundhouse-kicking action star, dead at 86: family
-
Supreme leader says Iran dealt enemies 'dizzying blow'
-
Audi team principal Wheatley in shock exit after two races
-
Spurs boss Tudor hopes for 'nice surprises' in relegation fight
-
Arsenal must prove they are winners in League Cup final, says Arteta
-
Record-breaking heat wave grips western US
-
Liverpool showdown brings back 'beautiful memories' for PSG coach Luis Enrique
-
IRA bomb victims drop civil court claim against Gerry Adams
-
Ntamack returns for Toulouse to face France rival Jalibert
-
Trump calls NATO allies 'cowards' over Iran
-
French jihadist jailed for life for Islamic State crimes against Yazidis
-
Chuck Norris, action man who inspired endless memes, dead at 86: family
-
Action movie star Chuck Norris has died: family statement
-
England stars have 'last chance' to earn World Cup spots: Tuchel
-
League Cup final a 'big moment' for Man City, says Guardiola
-
Injured Ronaldo misses Portugal World Cup friendlies
-
Liverpool condemn 'cowardly' racist abuse of Konate
-
Far from war, global fuel frustrations mount
-
German auto exports to China plunged a third in 2025: study
-
Coach Valverde to leave Bilbao at end of season
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
P.Sousa--PC